Music |
Video |
Movies |
Chart |
Show |
ARROW study: pralsetinib in RET fusion+ tumors (VJOncology) View | |
ARROW: clinical activity of pralsetinib in RET-fusion positive solid tumors (VJOncology) View | |
ARROW: precision targeted therapy with pralsetinib for RET fusion+ tumors (VJOncology) View | |
ARROW points the way for RET fusion-positive NSCLC treatment | Stephen Liu (Medicine Matters oncology) View | |
ARROW: an update on the registrational study (VJOncology) View | |
ASCO 2021 - Blueprint Medicines - ARROW Study Updated Results (HPR) View | |
Selpercatinib and Pralsetinib in RET + Disease - Lung Cancer Video Library (GRACE - Global Resource for Advancing Cancer Education) View | |
Rare Fusions in NSCLC: RET - Targeted Therapies in Lung Cancer 2023 (GRACE - Global Resource for Advancing Cancer Education) View | |
Designing clinical trials for precision oncology (VJOncology) View | |
Intracranial activity of selpercatinib in RET fusion positive NSCLC (VJOncology) View |